Montpellier-based SeqOne Genomics gets €20 million boost to make genetic testing more accessible

Providing an end-to-end genomic analysis platform, SeqOne Genomics has just landed €20 million in its mission to bring genomic analysis to everyone. ​​The round was led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors Elaia and IRDI Capital Investissement. 

The Montpellier-based healthtech company are focusing on the development of state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare diseases. The aim is to create a genomic analysis system that reduces the cost and resources that are currently needed for accurate genomic analysis – making genetic testing easier and more accessible, and accelerating the adoption of personalized medicine. 

With SeoqOne’s platform, high-resolution next generation sequencing (NGS) data can be efficiently analysed, providing a list of all genetic variants. With a proprietary machine learning-based variant prioritization engine, the variants that are medically relevant to each patient can be identified. The insights from the data will give crucial information to answer medical questions that influence patient treatment. 

The platform can be used to analyze a single patient or an entire family – diagnosing hereditary disorders as well as being able to analyse cancer samples and suggest therapeutic options. Primarily the platform is used by genomic experts who can then advise doctors on how best to pursue treatment. 

Founded in 2017, this new funding will be used to boost international sales of the platform, as well as continue to develop new collaborative genomic analysis tools that will enable communication between different medical teams to improve outcomes for patients with cancer and hereditary disease. 

Nicolas Philippe, Co-founder, and CEO of SeqOne Genomics said: “We have closed this round with investors who bring extensive experience in deep tech, healthcare, and biotherapy and who share our vision of building SeqOne into a global leader in personalised medicine. The funding will help us to enhance and commercialise our solution to make genomic analysis more accessible and affordable so that each patient can benefit from personalised medicine recommendations.”

Healthtech is a big growth area across Europe and genomic testing is a key trend in medical innovation. SeqOne’s platform is on track to contribute to medical advancements and this funding boost will go a long way to support its development.